| Released | Contributor | Author | Title | Pages | Price |
| 26-Dec-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: ANTARES PHARMA INC | 5 |
$25 |
| 26-Dec-2009 | Standard & Poor's Quantitative Report |
N/A
| Antares Pharma | 6 |
$25 |
| 25-Dec-2009 | Reuters Investment Profile |
N/A
| Antares Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 25-Dec-2009 | Pechala's Reports | Frantisek Pechala | ANTARES PHARMA INC (AIS=US) 12-months forecast | 1 |
$15 |
| 25-Dec-2009 | New Constructs, LLC |
N/A
| AIS: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 24-Dec-2009 | Pechala's Reports | Lubomir Pechala | ANTARES PHARMA INC (AIS=US) 2-weeks forecast | 1 |
$10 |
| 23-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for MEDICAL SUPPLIES | 18 |
$49 |
| 23-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ANTARES PHARMA -- AIS | 1 |
$4 |
| 23-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AIS , APPA , CPRX , NLTX , NBY , PCYC , VRUS , DDD -- DRUGS | 3 |
$4 |
| 22-Dec-2009 | Argus Research Corporation | David Coleman | Vickers Weekly Insider, 12/21/09 | 46 |
$50 |
0.51% Nasdaq 
Research Reports
